AstraZeneca Other Operating Income or Expenses 2010-2024 | AZN

AstraZeneca annual/quarterly other operating income or expenses history and growth rate from 2010 to 2024. Other operating income or expenses can be defined as the aggregate amount of all operating expenses either too small to report separately or that cannot be standardized into another Zacks field.
  • AstraZeneca other operating income or expenses for the quarter ending September 30, 2024 were $0.025B, a 64.29% decline year-over-year.
  • AstraZeneca other operating income or expenses for the twelve months ending September 30, 2024 were $259M, a 81.79% decline year-over-year.
  • AstraZeneca annual other operating income or expenses for 2023 were $1.34B, a 160.7% increase from 2022.
  • AstraZeneca annual other operating income or expenses for 2022 were $0.514B, a 65.55% decline from 2021.
  • AstraZeneca annual other operating income or expenses for 2021 were $1.492B, a 2.36% decline from 2020.
AstraZeneca Annual Other Operating Income or Expenses
(Millions of US $)
2023 $1,340
2022 $514
2021 $1,492
2020 $1,528
2019 $1,541
2018 $2,527
2017 $1,830
2016 $1,655
2015 $1,500
2014 $335
2013 $500
2012 $970
2011 $2,260
2010 $712
2009 $
AstraZeneca Quarterly Other Operating Income or Expenses
(Millions of US $)
2024-09-30 $25
2024-06-30 $60
2024-03-31 $67
2023-12-31 $107
2023-09-30 $70
2023-06-30 $784
2023-03-31 $379
2022-12-31 $189
2022-09-30 $106
2022-06-30 $122
2022-03-31 $97
2021-12-31 $147
2021-09-30 $37
2021-06-30 $128
2021-03-31 $1,180
2020-12-31 $640
2020-09-30 $287
2020-06-30 $121
2020-03-31 $480
2019-12-31 $500
2019-09-30 $335
2019-06-30 $113
2019-03-31 $593
2018-12-31 $1,002
2018-09-30 $439
2018-06-30 $617
2018-03-31 $469
2017-12-31 $848
2017-09-30 $143
2017-06-30 $603
2017-03-31 $236
2016-12-31 $1,120
2016-09-30 $110
2016-06-30 $370
2016-03-31 $55
2015-12-31 $471
2015-09-30 $453
2015-06-30 $199
2015-03-31 $377
2014-12-31 $273
2014-09-30 $118
2014-06-30 $117
2014-03-31 $-173
2013-12-31 $53
2013-09-30 $136
2013-06-30 $179
2013-03-31 $132
2012-12-31 $148
2012-09-30 $401
2012-06-30 $168
2012-03-31 $253
2011-12-31 $216
2011-09-30 $1,675
2011-06-30 $171
2011-03-31 $198
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $197.819B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94